Introduction

Dear Colleague,

Immune checkpoint inhibitors (ICIs) are changing clinical practice and outcomes in different diseases. But there are still many uncertainties and lack of evidence with these novel treatments.

On behalf of Institut Jules Bordet and ONCODISTINCT network, we invite you to participate in this survey entitled “Challenges for Clinical Practice with Immune Checkpoint Inhibitors monotherapy in the treatment of Non-Small Cell Lung Cancer (NSCLC)” led by Dr. Luis Castelo-Branco, Dr. Gilberto Morgan, Prof. Helena Canhão (Comprehensive Health Research Center, Nova Medical School, Lisbon, Portugal) Prof. Jan Van Meerbeeck (Head of the department of Pulmonology & Thoracic Oncology, Antwerp University Hospital, Belgium) and Prof. Ahmad Awada (Head of the Oncology Medicine Department at Jules Bordet Cancer Institute Brussels, Belgium). 

We are kindly requesting the participation of oncologists and thoracic oncologists and inquiring about their opinions and experience on these topics. This survey comes as a follow up to a recent review performed by our team on the subject for the European Society for Medical Oncology (ESMO).

Please answer the following questions considering your personal knowledge and experience. If you are not a medical doctor with some experience in lung cancer and ICIs or if you have already answered this survey, please do not proceed.

This survey should take approximately 10-12 minutes to complete.
Thank you so much for participating.
Page1 / 8
 

T